Systemic Blood Pressure in Heart Failure: The Next Frontier in Prognosis and Chronic HF Treatment?
- PMID: 35654523
- DOI: 10.1016/j.jchf.2022.02.017
Systemic Blood Pressure in Heart Failure: The Next Frontier in Prognosis and Chronic HF Treatment?
Keywords: TTR; heart failure; prognosis; survival; systemic hypertension; systolic blood pressure.
Conflict of interest statement
Funding Support and Author Disclosures Dr Bocchi has received consulting fees from Servier and AstraZeneca; has received subsidized travel/hotel/registration fees from Servier and Baldacci; has served on the steering committee of Servier and Novartis; has received research grant support through the Heart Institute (Incor) from Jansen, Bayer/Merck, AstraZeneca, and Boehringer Ingelheim; and has received honoraria from Servier, Novartis, and AstraZeneca. Dr Ventura has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart Failure.JACC Heart Fail. 2022 Jun;10(6):369-379. doi: 10.1016/j.jchf.2022.01.010. Epub 2022 Apr 6. JACC Heart Fail. 2022. PMID: 35654521
-
Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry.JACC Heart Fail. 2022 Jun;10(6):380-392. doi: 10.1016/j.jchf.2022.04.006. JACC Heart Fail. 2022. PMID: 35654522
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
